title: How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Wick
authors.forename: Michael
authors.initials: M
authors.lastname: Weller
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects*; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D008231:Lymphopenia / Q000139:chemically induced*; D009364:Neoplasm Recurrence, Local; D015996:Survival Rate; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide